During the past decade, NCT Heidelberg conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 7 clinical trials were completed, i.e. on average, 19.4% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 3 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "NCT Heidelberg" #1 sponsor was "German Cancer Research Center" with 6 trials, followed by "Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest" with 3 trials sponsored, "University Hospital Heidelberg" with 3 trials sponsored, "University Hospital Tuebingen" with 3 trials sponsored and "BioNTech SE" with 3 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "NCT Heidelberg" #1 collaborator was "University Hospital Heidelberg" with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "German Cancer Research Center" with 2 trials as a collaborator, "National Center for Tumor Diseases, Heidelberg" with 2 trials as a collaborator and "BioNTech SE" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "NCT Heidelberg" are "Breast Cancer" (5 trials), "Metastatic Breast Cancer" (4 trials), "Colorectal Cancer" (3 trials), "Bladder Cancer" (2 trials) and "Cancer" (2 trials). Many other conditions were trialed in "NCT Heidelberg" in a lesser frequency.

Most popular intervention types in "NCT Heidelberg" are "Drug" (29 trials), "Biological" (8 trials), "Other" (5 trials), "Procedure" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (2 trials), "Carboplatin" (2 trials), "Docetaxel" (2 trials), "Paclitaxel" (2 trials) and "Pembrolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "NCT Heidelberg" are 33 trials for "All" genders, 11 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "NCT Heidelberg". undefined are not yet recruiting, 11 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in NCT Heidelberg, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in NCT Heidelberg, 12 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".

NCT Heidelberg has several departments that took part in Clinical trials: "Division of Visceral Transplantation, Department of General, Visceral and Transplantation Surgery, University of Heidelberg" - 11 trials